Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update
- Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD)
- On track to submit new U.S….
